Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study
BTAs are underused in bone metastases patients in France. There is an urgent need to optimise bone metastases management in accordance with ESMO 2020 guidelines.
Authors
- Béatrice Bouvard (ORCID: https://orcid.org/0000-0003-1609-8113)
- Maëva Nolin (ORCID: https://orcid.org/0000-0002-6457-3639)
- Cyrille B. Confavreux (ORCID: https://orcid.org/0000-0002-9318-6785)
- Clarisse Marchal
- Pauline Bosco-Levy
- Manon Belhassen
- Eric Lehmann
- Gaelle Desameric
- Nicolas Girard
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Université de Bordeaux (FR)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Nantes Angers Le Mans (FR)
- Université Paris-Saclay (FR)
- Communauté urbaine de Lyon (FR)
- Hospices Civils de Lyon (FR)
- Bordeaux Population Health (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Hôpital Lyon Sud (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Université d'Angers (FR)
- Institut Curie (FR)
- HCL Technologies (India) (IN)
Publication Details
- Journal
- Journal of bone oncology
- Published
- 2026-01-04
- DOI
- https://doi.org/10.1016/j.jbo.2025.100738
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00